Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - In this poster, Dr. Michael Gorin presented quality of life outcomes from the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry. This goal of the registry is to assess the safety of active surveillance (AS) for small renal masses, 4cm or smaller, and currently includes 454 patients – 188 AS patients, 265 patients undergoing primary intervention and 21 patients crossing over from AS to intervention.

auaIn the context of the increasing importance of patient perception of quality of life (QOL) and quality of care under the Affordable Care Act, this study aimed to evaluate the effect of active surveillance on patient QOL. The study used the SF12 questionnaire as its QOL assessment tool, which allows for separation of perception of QOL into mental and physical components. A total of 1 028 SF12 questionnaires were completed with a median follow up of 1 year.

The authors found that patients undergoing immediate intervention had higher QOL scores at baseline and up to 1 year after enrollment compared to those managed with AS. This difference was attributable to a baseline difference between the groups with regards to pre-existing co-morbidities, as patients undergoing AS had more co-morbidities at baseline, which resulted in lower QOL scores in the physical domain. There was no difference in the mental health scores for QOL between the AS and intervention groups after 6 months post-enrollment suggesting that AS does not result in significant increases in anxiety, depression, or other mental health issues. Interestingly mental health QOL scores were found to increase slightly over time in the AS group.

Presented by Michael Gorin at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD USA

Written by Timothy Ito, MD, medical writer for UroToday.com

 

------------------

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting